Waturu Holding A/S
Company announcement nr. 58
Fredericia, February 4th 2021
Lost arbitration incurs additional costs
The company has been involved in an arbitration case concerning an advisory fee, as described in company announcement no. 42, "Addition of note to the interim report 2020".
The case is lost and the amount owed including additional costs of approx. 1,5 MDKK is paid.
About Waturu Holding A/S
Waturu Holding A/S is a Greentech company, which develops innovative water technology for heating or treating water, with the focus on ensuring bacteria-free water and reducing water and energy consumption for heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a major shareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S.
Further information:
CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
Certified Adviser
Please see company announcement no. 55
Nasdaq First North Growth Market
Important links:
Websites:
www.waturu.com
Financial reports:
www.waturu.com/documents
Further press related news:
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.14.10.2025 01:30:00 CEST | Press release
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Bombardier Inc.13.10.2025 22:02:56 CEST | Press release
Bombardier Global 8000, The World’s Fastest Business Jet, Gets Even Faster with a New Top Speed of Mach 0.95
Zymeworks Inc.13.10.2025 22:00:00 CEST | Press release
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Bombardier Inc.13.10.2025 21:00:00 CEST | Press release
Bombardier Unveils Comlux as Global 8000 Aircraft Customer, Delivery Confirmed for 2026
Cosmos Health Inc.13.10.2025 20:05:46 CEST | Press release
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom